July 10, 2026Journal of Clinical OncologyCARES (CAEL101-301 / CAEL101-302; NCT04504825 & NCT04512235)
Anselamimab Misses Primary Endpoint Overall but Cuts Mortality 62% in Kappa AL Amyloidosis
Pooled analysis of the phase III CARES program (CAEL101-301 and CAEL101-302, n=406) testing whether adding the antifibril monoclonal antibody anselamimab to standard anti-plasma cell dyscrasia therapy improves a composite mortality/hospitalization endpoint in advanced (Mayo stage IIIa/IIIb) AL amyloidosis